The Conversation (0)
Menafn.com reports that Teva Pharmaceutical Industries (NYSE:TEVA) has received FDA approval for TREANDA (bendamustine HCI) Injection, a new formulation of the currently approved TREANDA (bendamustine HCI) for Injection.
Menafn.com reports that Teva Pharmaceutical Industries (NYSE:TEVA) has received FDA approval for TREANDA (bendamustine HCI) Injection, a new formulation of the currently approved TREANDA (bendamustine HCI) for Injection.
As quoted in the market news:
The company added TREANDA is indicated for use in patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and in patients with chronic lymphocytic leukemia (CLL).
This new liquid formulation removes the step of reconstituting lyophilized powder with sterile water prior to adding the medicine to the dilutent and administering to a patient, said the company.